All Stories

  1. A Comparative Analysis Between Original and Updated Glucose Management Indicator and Glycated Haemoglobin Across Continuous Glucose Monitoring Sensors in Type 1 Diabetes
  2. The Case for Evaluating Continuous Glucose Monitoring as a Diagnostic Tool for Diabetes
  3. Glycaemic Changes After Semaglutide Discontinuation in Adults With Type 1 Diabetes Using Automated Insulin Delivery: Analysis of the ADJUST ‐ T1D Exte...
  4. Impact of Pharmacy Benefit Manager Organizations on Diabetes Management
  5. Management of Pregnancy in Type 1 Diabetes Using a Novel Automated Insulin Delivery System
  6. How Continuous Glucose Monitoring Reports Inform Clinical Decision-Making for Older Adults With Type 2 Diabetes: Mapping Clinical Workflow to Situation Awareness
  7. Integrating the Glycemia Risk Index Into Clinical Practice and Research: A Consensus Report
  8. Rethinking control‐ IQ + technology: Simple strategies for easy optimization
  9. Assessing Time Below Range as a Predictor of Severe Hypoglycemia: Insights From Six Clinical Trials
  10. Association of HbA1c and an updated glucose management indicator (uGMI) with incident diabetic retinopathy in adults with type 1 diabetes: a longitudinal study
  11. iCoDE-2 September 18, 2025 Steering Committee Final Meeting Summary Report
  12. Hypophosphatasia and Type 1 Diabetes: A Pilot Study and Review of Literature
  13. Time in Range and Incident Diabetic Retinopathy: Clinical and Economic Evidence From Real-World Type 1 Diabetes Care
  14. Recombinant Human GH in Managing Refractory Hypoglycemia in a Young Patient With Embryonal Rhabdomyosarcoma
  15. Association Between Time-in-Range and Diabetic Retinopathy: Learnings from DCCT to Recent Times
  16. Navigating Automated Insulin Delivery for Type 1 Diabetes Management During Pregnancy
  17. Changes in A1C Versus GMI Across Glycemic Categories in Clinical Trials of Type 1 Diabetes
  18. Quantifying Environmental Waste From Diabetes Devices in the U.S.
  19. Randomized, Crossover Trial of Control-IQ Technology with a Lower Treatment Range and a Modified Meal Bolus Module in Adults, Adolescents, Children, and Preschoolers with Varying Levels of Baseline Glycemic Control
  20. Treatment satisfaction and time in range after 16 weeks of treatment with iGlarLixi in insulin‐naive adults with suboptimally controlled type 2 diabetes
  21. Progression of Diabetic Retinopathy After Initiation of Automated Insulin Delivery System in Adults With Type 1 Diabetes
  22. Prescribed Total Daily Insulin Dose and Predictors of Insulin Dose for Adults with Type 2 Diabetes on Multiple Daily Injections of Insulin: A Retrospective Cohort Study
  23. Determinants of Liraglutide Treatment Discontinuation in Type 1 Diabetes: A Post Hoc Analysis of ADJUNCT ONE and ADJUNCT TWO Randomized Placebo-Controlled Clinical Studies
  24. Consensus Report on Glucagon-Like Peptide-1 Receptor Agonists as Adjunctive Treatment for Individuals With Type 1 Diabetes Using an Automated Insulin Delivery System
  25. Prediction of Incident Diabetic Retinopathy in Adults With Type 1 Diabetes Using Machine Learning Approach: An Exploratory Study
  26. Insulin Titration Recommendations When Using Glucagon-Like Peptide 1 Receptor Agonist Therapy in Adults With Type 1 Diabetes
  27. Navigating the New Frontiers of Hyperglycemic Crisis Management: Unveiling the Latest American Diabetes Association Consensus Report
  28. Association between continuous glucose monitoring metrics and clinical outcomes in adults with type 1 diabetes in a real-world setting
  29. The Association of High and Low Glycation With Incident Diabetic Retinopathy in Adults With Type 1 Diabetes
  30. Changes in Basal and Bolus Insulin Requirements with Tirzepatide as an Adjunctive Therapy in Adults with Type 1 Diabetes Using Tandem Control-IQ
  31. Reduced Efficacy of Glucagon-Like Peptide-1 Receptor Agonists Therapy in People With Type 1 Diabetes and Genetic Forms of Obesity
  32. Continuous Glucose Monitoring for Prediabetes: What Are the Best Metrics?
  33. Time in Range Is Associated with Incident Diabetic Retinopathy in Adults with Type 1 Diabetes: A Longitudinal Study
  34. Maternal diabetes and fracture risk in offspring: a population-based analysis
  35. Control-IQ Technology Use in Individuals With High Insulin Requirements: Results From the Multicenter Higher-IQ Trial
  36. Safety and Efficacy of Switching SAR341402 Insulin Aspart and Originator Insulin Aspart vs Continuous Use of Originator Insulin Aspart in Adults With Type 1 Diabetes: The GEMELLI X Trial
  37. Safety and Feasibility Evaluation of Automated User Profile Settings Initialization and Adaptation With Control-IQ Technology
  38. Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study
  39. Limitations of Reporting Time Below Range as a Percentage
  40. Pharmacokinetic similarity of switching SAR341402 insulin aspart biosimilar and NovoLog insulin aspart versus continuous use of
  41. Bone Structure and Turnover in Postmenopausal Women With Long‐Standing Type 1 Diabetes
  42. Skeletal Health in Patients With Mitochondrial Diabetes: Case Series and Review of Literature
  43. Minimum Sampling Duration for Continuous Glucose Monitoring Metrics to Achieve Representative Glycemic Outcomes in Suboptimal Continuous Glucose Monitor Use
  44. Association Between Diabetes Technology Use and Glycemic Outcomes in Adults With Type 1 Diabetes Over a Decade
  45. Changes in the glycaemia risk index and its association with other continuous glucose monitoring metrics after initiation of an automated insulin delivery system in adults with type 1 diabetes
  46. Discordance Between Glucose Management Indicator and Glycated Hemoglobin in People Without Diabetes
  47. Optimal Sampling Duration for Continuous Glucose Monitoring for the Estimation of Glycemia Risk Index
  48. Higher Prevalence of Hypoglycemia and Unsafe Driving Practices in Adults With Type 1 Diabetes
  49. Relationship Between Daytime Versus Nighttime Continuous Glucose Monitoring Metrics with A1C in Adults with Type 1 Diabetes
  50. Efficacy and Safety of Tandem Control IQ Without User-Initiated Boluses in Adults with Uncontrolled Type 1 Diabetes
  51. Impact of Different Types of Data Loss on Optimal Continuous Glucose Monitoring Sampling Duration
  52. Retained Diabetes Devices—A Literature Review
  53. Health Care Professionals’ Perspectives on Use of Diabetes Technologies for Managing Visually Impaired Patients With Diabetes
  54. Effect of divergent continuous glucose monitoring technologies on glycaemic control in type 1 diabetes mellitus: A systematic review and meta‐analysis of randomised controlled trials
  55. Continuous Glucose Monitoring Initiation Within First Year of Type 1 Diabetes Diagnosis Is Associated With Improved Glycemic Outcomes: 7-Year Follow-Up Study
  56. Differentiating Diabetic Ketoacidosis and Hyperglycemic Ketosis Due to Cannabis Hyperemesis Syndrome in Adults With Type 1 Diabetes
  57. Relationship Between Time-in-Range, HbA1c, and the Glucose Management Indicator in Pregnancies Complicated by Type 1 Diabetes
  58. Off‐label use of sodium glucose co‐transporter inhibitors among adults in type 1 diabetes exchange registry
  59. A randomized controlled trial of transition from insulin pump to multiple daily injections using insulin degludec
  60. Health-related quality of life in parents and partners of people with type 1 diabetes: Development and validation of type 1 diabetes and life (T1DAL) measures.
  61. Inequity in Racial-Ethnic Representation in Randomized Controlled Trials of Diabetes Technologies in Type 1 Diabetes: Critical Need for New Standards
  62. Acute Hyperinsulinemia Alters Bone Turnover in Women and Men With Type 1 Diabetes
  63. Undertreatment of cardiovascular risk factors in the type 1 diabetes exchange clinic network ( United States ) and the prospective diabetes follow‐up (Germany/Austria) registries
  64. Suicide via Intentional Insulin Overdose Through First Commercial Hybrid Closed-Loop
  65. Efficacy and Safety of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart in People with Diabetes Treated for 26 Weeks with Multiple Daily Injections in Combination with Insulin Glargine: A Randomized Open-Label Trial (GEMELLI 1)
  66. Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes: Findings from Prospective Real-life T1D Exchange Registry
  67. Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes
  68. Bone Mineral Density across the Lifespan in Patients with Type 1 Diabetes
  69. Cannabis Use Is Associated With Increased Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes: Findings From the T1D Exchange Clinic Registry
  70. Letter to editor in response to article published by Leanza et al.
  71. Type 1 diabetes onset at young age is associated with compromised bone quality
  72. Association Between Cannabis Use and Risk for Diabetic Ketoacidosis in Adults With Type 1 Diabetes
  73. Glycemic Outcomes with Early Initiation of Continuous Glucose Monitoring System in Recently Diagnosed Patients with Type 1 Diabetes
  74. Determinants of fracture in adults with type 1 diabetes in the USA: Results from the T1D Exchange Clinic Registry
  75. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial
  76. Gender differences in diabetes self-care in adults with type 1 diabetes: Findings from the T1D Exchange clinic registry
  77. Bone health in type 1 diabetes
  78. Diabetes Technology Use Among Pregnant and Nonpregnant Women with T1D in the T1D Exchange
  79. Bone and Vascular Health in Postmenopausal Women with Type 1 Diabetes
  80. Contemporary Prevalence of Diabetic Neuropathy in Type 1 Diabetes (T1D)—Findings from the T1D Exchange
  81. Coronary Artery Calcium Trajectory Predicts Coronary Artery Disease Events—The CACTI Study
  82. Increased HbA1c Variability May Shorten Time to Microalbuminuria Development in Type 1 Diabetes (T1D)
  83. Risk Factors for Cardiovascular Disease (CVD) in Adults with Type 1 Diabetes (T1D)
  84. Severe hypoglycemia is associated with high risk for falls in adults with type 1 diabetes
  85. Bone mineral content and bone density is lower in adolescents with type 1 diabetes : A brief report from the RESISTANT and EMERALD studies
  86. Accuracy of a Factory-Calibrated, Real-Time Continuous Glucose Monitoring System During 10 Days of Use in Youth and Adults with Diabetes
  87. Performance of a Factory-Calibrated Real-Time Continuous Glucose Monitoring System Utilizing an Automated Sensor Applicator
  88. Methyldopa blocks MHC class II binding to disease-specific antigens in autoimmune diabetes
  89. Role of bicarbonate supplementation on urine uric acid crystals and diabetic tubulopathy in adults with type 1 diabetes
  90. Complications With Insulin Pump Therapy vs Insulin Injection Therapy
  91. Olmesartan in Management of Proteinuria
  92. Trabecular bone quality is lower in adults with type 1 diabetes and is negatively associated with insulin resistance
  93. Reported gastroparesis in adults with type 1 diabetes (T1D) from the T1D Exchange clinic registry
  94. Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel stud...
  95. Glycemic Control With Early Initiation of Continuous Glucose Monitoring System in Adults With Recently Diagnosed Type 1A Diabetes
  96. Efficacy and Safety of Mini-dose Glucagon for Treatment of Non-severe Hypoglycemia in Adults with Type 1 Diabetes
  97. Bone mineral density at femoral neck and lumbar spine in adults with type 1 diabetes: a meta-analysis and review of the literature
  98. Role of Mobile Technology to Improve Diabetes Care in Adults with Type 1 Diabetes: The Remote-T1D Study iBGStar® in Type 1 Diabetes Management
  99. REPLACE-BG: A Randomized Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Well-Controlled Type 1 Diabetes
  100. A novel option for prandial insulin therapy: inhaled insulin
  101. An Unusual Cause of Recurrent Diabetic Ketoacidosis in Type 1 Diabetes
  102. Drug Delivery to CNS: Challenges and Opportunities with Emphasis on Biomaterials Based Drug Delivery Strategies
  103. Pulmonary Function Tests in Sickle Cell Disease
  104. Insulin delivery methods: Past, present and future
  105. Psychological Aspects Related to Diabetes Mellitus
  106. Pustulovesicular skin eruption as presenting feature of incomplete kawasaki disease
  107. Managing diabetes in the digital age
  108. Comment on Weber et al. Type 1 Diabetes Is Associated With an Increased Risk of Fracture Across the Life Span: A Population-Based Cohort Study Using The Health Improvement Network (THIN). Diabetes Care 2015;38:1913–1920
  109. Risk factors for proteinuria and renal insufficiency in Asian Indian patients with type 2 diabetes
  110. Diabetes in India
  111. Type 1 diabetes and risk of fracture: meta‐analysis and review of the literature
  112. Association Between Bone Mineral Density and type 1 Diabetes Mellitus: A meta-Analysis of Observational Studies
  113. Short-term efficacy of recombinant human GH therapy in cured acromegaly patients with GH deficiency: a single-center experience
  114. Comment on Liu et al. Latent Autoimmune Diabetes in Adults With Low-Titer GAD Antibodies: Similar Disease Progression With Type 2 Diabetes: A Nationwide, Multicenter Prospective Study (LADA China Study 3). Diabetes Care 2015;38:16–21
  115. New Medications for the Treatment of Diabetes
  116. Closed-Loop System in the Management of Diabetes: Past, Present, and Future
  117. Effect of Vitamin D Replacement on Hemoglobin Concentration in Subjects with Concurrent Iron-Deficiency Anemia and Vitamin D Deficiency: A Randomized, Single-Blinded, Placebo-Controlled Trial
  118. Newer Therapies for Diabetes Management
  119. Effect of 25 ( OH ) D replacements in patients with primary hyperparathyroidism ( PHPT ) and coexis...
  120. Choice of fluid therapy in patients of craniopharyngioma in the perioperative period: A hospital-based preliminary study
  121. Type 1 diabetes and osteoporosis: A review of literature
  122. Drug utilization pattern and pharmacoeconomic analysis in geriatric medical in-patients of a tertiary care hospital of India
  123. Pregnancy Outcome in Hyperthyroidism: A Case Control Study
  124. Non-islet cell tumor-induced hypoglycemia: a report of five cases and brief review of the literature
  125. Use of Non-Insulin Therapies for Type 1 Diabetes
  126. The Future of Basal Insulin
  127. Fusarium falciforme Infection of Foot in a Patient with Type 2 Diabetes Mellitus: A Case Report and Review of the Literature
  128. Thyroid autoimmunity and obstetric outcomes in women with recurrent miscarriage: a case-control study
  129. Genome-Wide Association Study for Type 2 Diabetes in Indians Identifies a New Susceptibility Locus at 2q21
  130. Endothelial Nitric Oxide Synthase Gene Polymorphism and the Risk of Diabetic Neuropathy in Asian Indian Patients with Type 2 Diabetes
  131. Angiotensin‐converting enzyme gene variants interact with the renin–angiotensin system pathway to confer risk and protection against type 2 diabetic retinopathy
  132. Coexistence of gonadal dysgenesis and Mayer-Rokitansky-Kuster-Hauser syndrome in 46, XX female: A case report and review of literature
  133. ACACβ gene (rs2268388) and AGTR1 gene (rs5186) polymorphism and the risk of nephropathy in Asian Indian patients with type 2 diabetes
  134. Chief cell and clear cell parathyroid adenoma do not influence clinical and biochemical expression of the sporadic primary hyperparathyroidism
  135. Association of an Osteopontin gene promoter polymorphism with susceptibility to diabetic nephropathy in Asian Indians
  136. STUDY OF HEMATOLOGICAL PARAMETERS AMONG NEONATES ADMITTED WITH NEONATAL JAUNDICE
  137. A bony swelling on the forehead: an uncommon manifestation of a well-known metabolic disease
  138. Microbial Profile and Utility of Soft Tissue, Pus, and Bone Cultures in Diagnosing Diabetic Foot Infections
  139. Authors′ reply
  140. Influence of age and gender on presentation of symptomatic primary hyperparathyroidism
  141. Carotid intima media thickness in patients with sporadic idiopathic hypoparathyroidism: a pilot study
  142. Oro-mandibular manifestations of primary hyperparathyroidism
  143. Congestive heart failure in acromegaly: A review of 6 cases
  144. Large but benign adrenal mass: Adrenal oncocytoma
  145. Pulmonary function tests in patients with primary hyperparathyroidism
  146. Pituitary dysfunction in survivors of spontaneous subarachnoid hemorrhage of anterior communicating artery and middle cerebral artery aneurysms: A comparative study
  147. Clinical Scoring System to Predict Malarial Fever: A Prospective Study
  148. High prevalence of cholelithiasis in primary hyperparathyroidism: a retrospective analysis of 120 cases
  149. Pituitary metastasis as a presenting manifestation of silent systemic malignancy: A retrospective analysis of four cases
  150. Vanishing adrenal mass
  151. Fixed drug eruption with ornidazole having cross‐sensitivity to secnidazole but not to other nitro‐imidazole compounds: a case report
  152. Prevalence of diabetes, metabolic syndrome, and cardiovascular risk factors in US Asian Indians: results from a national study
  153. Primary hyperparathyroidism with unilateral proptosis
  154. Consensus statement on childhood tuberculosis
  155. Statins
  156. Severe myocardial depression in a patient with aluminium phosphide poisoning: A clinical, electrocardiographical and histopathological correlation
  157. Assessing the knowledge, attitudes and practice of type 2 diabetes among patients of Saurashtra region, Gujarat
  158. Gatifloxacin-induced prolongation of QTC interval
  159. “Diabetic Foot” Complicated by Pneumococcal Cellulitis